|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:USP32-UBE2O (FusionGDB2 ID:96721) |
Fusion Gene Summary for USP32-UBE2O |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: USP32-UBE2O | Fusion gene ID: 96721 | Hgene | Tgene | Gene symbol | USP32 | UBE2O | Gene ID | 84669 | 63893 |
| Gene name | ubiquitin specific peptidase 32 | ubiquitin conjugating enzyme E2 O | |
| Synonyms | NY-REN-60|USP10 | E2-230K | |
| Cytomap | 17q23.1-q23.2 | 17q25.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | ubiquitin carboxyl-terminal hydrolase 32deubiquitinating enzyme 32renal carcinoma antigen NY-REN-60ubiquitin specific protease 32ubiquitin thioesterase 32ubiquitin thiolesterase 32ubiquitin-specific-processing protease 32 | (E3-independent) E2 ubiquitin-conjugating enzymeE2/E3 hybrid ubiquitin-protein ligase UBE2Oubiquitin carrier protein Oubiquitin conjugating enzyme E2Oubiquitin-conjugating enzyme E2 of 230 kDaubiquitin-conjugating enzyme E2-230Kubiquitin-protein lig | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | . | |
| Ensembl transtripts involved in fusion gene | ENST00000300896, ENST00000592339, ENST00000393003, ENST00000586881, | ENST00000319380, ENST00000587581, | |
| Fusion gene scores | * DoF score | 36 X 25 X 11=9900 | 4 X 5 X 2=40 |
| # samples | 42 | 5 | |
| ** MAII score | log2(42/9900*10)=-4.55896729218821 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(5/40*10)=0.321928094887362 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: USP32 [Title/Abstract] AND UBE2O [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | USP32(58300772)-UBE2O(74401654), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | USP32-UBE2O seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. USP32-UBE2O seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | UBE2O | GO:0006513 | protein monoubiquitination | 23455153|24703950 |
| Tgene | UBE2O | GO:0030513 | positive regulation of BMP signaling pathway | 23455153 |
| Fusion gene breakpoints across USP32 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across UBE2O (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | BRCA | TCGA-C8-A273-01A | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - |
Top |
Fusion Gene ORF analysis for USP32-UBE2O |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000300896 | ENST00000319380 | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - |
| 5CDS-intron | ENST00000300896 | ENST00000587581 | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - |
| Frame-shift | ENST00000592339 | ENST00000319380 | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - |
| 5CDS-intron | ENST00000592339 | ENST00000587581 | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - |
| intron-3CDS | ENST00000393003 | ENST00000319380 | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - |
| intron-intron | ENST00000393003 | ENST00000587581 | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - |
| intron-3CDS | ENST00000586881 | ENST00000319380 | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - |
| intron-intron | ENST00000586881 | ENST00000587581 | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000300896 | USP32 | chr17 | 58300772 | - | ENST00000319380 | UBE2O | chr17 | 74401654 | - | 6757 | 1803 | 195 | 5264 | 1689 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000300896 | ENST00000319380 | USP32 | chr17 | 58300772 | - | UBE2O | chr17 | 74401654 | - | 0.001402685 | 0.9985973 |
Top |
Fusion Genomic Features for USP32-UBE2O |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for USP32-UBE2O |
| Go to FGviewer for the breakpoints of chr17:58300772-chr17:74401654 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | . |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | USP32 | chr17:58300772 | chr17:74401654 | ENST00000300896 | - | 14 | 34 | 241_252 | 536.0 | 1605.0 | Calcium binding | 1 |
| Hgene | USP32 | chr17:58300772 | chr17:74401654 | ENST00000300896 | - | 14 | 34 | 277_288 | 536.0 | 1605.0 | Calcium binding | 2 |
| Hgene | USP32 | chr17:58300772 | chr17:74401654 | ENST00000300896 | - | 14 | 34 | 228_263 | 536.0 | 1605.0 | Domain | EF-hand 2 |
| Hgene | USP32 | chr17:58300772 | chr17:74401654 | ENST00000300896 | - | 14 | 34 | 264_299 | 536.0 | 1605.0 | Domain | EF-hand 3 |
| Hgene | USP32 | chr17:58300772 | chr17:74401654 | ENST00000300896 | - | 14 | 34 | 91_126 | 536.0 | 1605.0 | Domain | EF-hand 1 |
| Tgene | UBE2O | chr17:58300772 | chr17:74401654 | ENST00000319380 | 0 | 18 | 812_882 | 139.0 | 1293.0 | Coiled coil | Ontology_term=ECO:0000255 | |
| Tgene | UBE2O | chr17:58300772 | chr17:74401654 | ENST00000319380 | 0 | 18 | 953_1113 | 139.0 | 1293.0 | Domain | UBC core | |
| Tgene | UBE2O | chr17:58300772 | chr17:74401654 | ENST00000319380 | 0 | 18 | 512_536 | 139.0 | 1293.0 | Motif | Nuclear localization signal |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | USP32 | chr17:58300772 | chr17:74401654 | ENST00000300896 | - | 14 | 34 | 369_585 | 536.0 | 1605.0 | Domain | DUSP |
| Hgene | USP32 | chr17:58300772 | chr17:74401654 | ENST00000300896 | - | 14 | 34 | 734_1567 | 536.0 | 1605.0 | Domain | Note=USP |
| Tgene | UBE2O | chr17:58300772 | chr17:74401654 | ENST00000319380 | 0 | 18 | 2_43 | 139.0 | 1293.0 | Compositional bias | Note=Ala-rich |
Top |
Fusion Gene Sequence for USP32-UBE2O |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000300896_ENST00000319380_TCGA-C8-A273-01A_USP32_chr17_58300772_-_UBE2O_chr17_74401654_length(transcript)=6757nt_BP=1803nt ACGTGATCCGGCATGGAGGCGGTGGCGGCGACCGGGAGGAGCCGCCGGGGCAGAAGCCGCACTTGTTAGTGTGGGGGGAGGTGGGGGCGG GGGACGCCGACACCGTCACCGTCACCCAGGGACGCCGAGGAGAAGGCGGGAGGGGGGTGGGGGCGAGATCAGGCTCCGACCCCCCGCCGA GGGGATGAGGGGAGCATGGGTGCCAAGGAGTCACGGATCGGATTCCTCAGCTACGAGGAGGCGCTGAGGAGAGTTACAGATGTAGAGCTA AAACGACTGAAGGATGCTTTCAAGAGGACCTGTGGACTCTCATATTACATGGGCCAGCACTGCTTCATCCGGGAAGTGCTTGGGGATGGA GTGCCTCCAAAGGTTGCTGAGGTGATTTACTGTTCTTTTGGTGGAACATCCAAAGGGCTGCACTTCAATAATTTAATAGTTGGACTTGTC CTCCTTACAAGAGGCAAAGATGAAGAGAAAGCAAAATACATTTTTAGTCTTTTTTCAAGTGAATCTGGGAACTATGTTATACGGGAAGAA ATGGAAAGAATGCTCCACGTGGTGGATGGTAAAGTCCCAGATACACTCAGGAAGTGTTTCTCAGAGGGTGAAAAGGTAAACTATGAAAAG TTTAGAAATTGGCTTTTTCTAAACAAAGATGCTTTTACTTTCTCTCGATGGCTTCTATCTGGAGGTGTGTATGTTACCCTCACTGATGAT AGTGATACTCCTACTTTCTACCAAACTCTGGCTGGAGTCACACATTTGGAGGAATCAGACATCATTGATCTTGAGAAACGCTATTGGTTA TTGAAGGCTCAATCCCGGACTGGACGATTTGATTTAGAGACATTTGGCCCATTGGTTTCACCACCTATTCGTCCATCTCTAAGTGAAGGT TTGTTTAATGCTTTTGATGAAAATCGTGACAATCACATAGATTTTAAGGAGATATCCTGTGGGTTATCAGCCTGTTGCAGGGGACCCCTG GCTGAAAGACAAAAATTTTGCTTCAAGGTATTTGATGTTGACCGTGATGGAGTTCTCTCCAGGGTTGAACTGAGAGACATGGTGGTTGCA CTTTTAGAAGTCTGGAAGGACAACCGCACTGATGATATTCCTGAATTACATATGGATCTCTCTGATATTGTAGAAGGCATACTGAATGCA CATGACACCACAAAGATGGGTCATCTTACTCTGGAAGACTATCAGATCTGGAGTGTGAAAAATGTTCTTGCCAATGAGTTTTTGAACCTC CTTTTCCAGGTGTGTCACATAGTTCTGGGGTTAAGACCAGCTACTCCGGAAGAAGAAGGACAAATTATTAGAGGATGGTTAGAACGAGAG AGCAGGTATGGTCTGCAAGCAGGACACAACTGGTTTATCATCTCCATGCAGTGGTGGCAACAGTGGAAAGAATATGTCAAATACGATGCC AACCCTGTGGTAATTGAGCCATCATCTGTTTTGAATGGAGGAAAATACTCATTTGGAACTGCAGCCCATCCTATGGAGCAGGTCGAAGAT AGAATTGGAAGCAGCCTCAGTTACGTGAATACTACAGAAGAGAAATTTTCAGACAACATTTCTACTGCATCTGAAGCCTCAGAAACTGCT GGCAGCGGCTTTCTGTATTCTGCCACACCAGGGGCAGATGTTTGCTTTGCTCGACAACATAACACTTCTGACAATAACAACCAGTGTTTG CTGGGAGCCAATGGGAATATTTTGTTGCACCTTAACCCTCAGAAACCAGGGGCTATTGATAATCAGCCATTAGTAACTCAAGAACCAGTA AAGCTGAAACTAGAGGACCGTTCTGTGGTGCCCCGAGATGTGGTCCGGCACATGCGATCCACCGACAGTCAGTGTGGCACGGTGATCGAC GTCAACATCGACTGTGCCGTCAAGCTCATCGGCACCAACTGCATCATCTATCCCGTCAACAGCAAGGACCTGCAGCACATCTGGCCCTTC ATGTATGGGGACTACATTGCCTATGACTGCTGGCTGGGGAAGGTCTACGACTTGAAGAACCAGATCATCCTGAAGCTATCCAACGGCGCC AGGTGCTCCATGAACACGGAAGATGGCGCCAAGCTCTACGACGTCTGCCCGCACGTCAGCGACTCGGGTCTCTTCTTCGATGATTCCTAT GGCTTCTACCCAGGCCAGGTGCTCATTGGCCCTGCCAAGATCTTCTCCAGCGTCCAGTGGCTGTCAGGTGTCAAGCCCGTGCTCAGCACC AAGAGCAAGTTCCGAGTGGTGGTGGAAGAGGTGCAGGTTGTAGAGTTGAAAGTTACATGGATTACCAAGAGTTTCTGTCCAGGGGGCACG GACAGCGTCAGCCCCCCACCCTCTGTCATCACCCAGGAAAACCTAGGCAGGGTGAAGCGTCTCGGATGCTTTGACCATGCTCAGCGGCAG CTTGGGGAGCGCTGTCTGTATGTCTTCCCAGCCAAGGTAGAGCCAGCCAAGATTGCCTGGGAATGTCCAGAAAAAAACTGCGCCCAGGGG GAGGGCTCTATGGCCAAGAAGGTGAAGCGCCTGTTGAAGAAGCAGGTTGTGCGGATCATGTCATGCTCCCCAGACACCCAGTGTTCCCGG GACCATTCCATGGAAGACCCAGACAAGAAGGGGGAATCCAAAACCAAGAGCGAAGCGGAGTCTGCCAGCCCTGAGGAGACGCCCGATGGC TCTGCCAGTCCAGTGGAGATGCAGGACGAGGGTGCAGAGGAGCCCCACGAGGCAGGAGAGCAGCTGCCCCCATTCCTGCTAAAAGAAGGC AGAGATGACAGGCTGCACTCGGCAGAGCAGGACGCAGATGATGAGGCTGCTGATGACACGGACGACACCAGTTCGGTGACCTCCTCTGCC AGCTCCACCACTTCCTCCCAGAGCGGCAGCGGCACGAGTCGCAAAAAGAGCATCCCCTTGTCCATCAAGAACTTAAAGCGCAAACACAAG AGGAAGAAGAATAAAATCACTCGAGACTTCAAGCCAGGGGACAGGGTGGCAGTGGAGGTGGTGACCACGATGACCTCAGCCGACGTGATG TGGCAGGATGGCTCCGTGGAATGCAACATCCGCTCCAACGACCTCTTCCCTGTGCACCACCTGGACAACAACGAGTTCTGCCCTGGAGAC TTCGTGGTAGATAAGCGAGTCCAGAGCTGTCCAGACCCTGCTGTCTACGGTGTGGTACAGTCTGGGGACCACATCGGCCGTACCTGCATG GTGAAGTGGTTCAAGCTGAGGCCGAGTGGGGACGACGTGGAGCTGATTGGAGAAGAGGAAGATGTGAGTGTTTACGACATTGCTGACCAC CCTGACTTTAGGTTCCGTACAACTGACATCGTCATCCGCATCGGCAATACTGAGGATGGGGCTCCTCACAAGGAGGATGAGCCATCGGTG GGCCAGGTGGCCCGTGTGGACGTCAGCAGCAAGGTGGAGGTGGTGTGGGCTGACAACTCAAAGACCATCATCCTGCCCCAGCACTTGTAC AACATAGAGTCTGAGATTGAGGAGTCAGACTACGATTCGGTAGAAGGCAGCACCAGCGGGGCATCCTCGGATGAATGGGAAGATGATAGT GACAGCTGGGAGACGGACAATGGGCTGGTGGAGGACGAGCACCCCAAGATAGAGGAGCCCCCCATCCCACCCCTGGAGCAGCCGGTGGCC CCTGAGGACAAGGGAGTGGTGATCAGTGAAGAGGCAGCCACAGCTGCCGTCCAGGGGGCTGTGGCCATGGCTGCCCCCATGGCCGGGCTG ATGGAGAAGGCTGGCAAGGACGGGCCACCCAAGAGCTTCCGGGAGTTGAAAGAGGCCATCAAGATCCTGGAGAGCCTCAAGAACATGACT GTGGAGCAGCTGCTGACGGGCTCGCCCACCTCTCCGACTGTGGAGCCTGAGAAGCCAACTCGGGAGAAGAAGTTTCTGGATGACATCAAG AAGCTACAGGAAAACCTCAAGAAGACCCTGGACAATGTGGCCATTGTAGAGGAGGAGAAGATGGAAGCAGTGCCCGACGTAGAGCGCAAG GAGGACAAGCCCGAGGGGCAGTCACCTGTGAAGGCTGAGTGGCCCAGCGAAACCCCGGTGCTGTGCCAGCAGTGTGGCGGCAAGCCTGGC GTCACCTTCACCAGCGCCAAGGGCGAGGTCTTCTCCGTACTGGAGTTTGCACCCTCAAATCATTCTTTTAAGAAAATTGAGTTCCAGCCT CCAGAAGCCAAGAAGTTCTTCAGCACAGTGCGGAAGGAGATGGCGCTGCTGGCTACCTCACTGCCTGAGGGCATCATGGTCAAGACTTTT GAAGATAGAATGGACCTCTTCTCAGCTCTCATCAAGGGCCCCACTCGAACCCCCTACGAGGATGGCCTCTACTTGTTTGACATCCAGCTC CCCAACATCTACCCAGCCGTGCCCCCCCACTTCTGCTACCTCTCCCAATGCAGTGGCCGCCTGAACCCCAACCTGTATGACAATGGGAAG GTGTGTGTCAGCCTCCTGGGCACCTGGATTGGAAAGGGGACAGAGAGGTGGACAAGCAAGTCCAGCCTTCTCCAGGTGCTCATCTCCATC CAAGGTCTGATCCTGGTAAATGAACCATACTACAACGAAGCCGGCTTCGACAGTGACCGAGGCCTGCAGGAAGGCTATGAAAACAGTCGC TGTTACAATGAGATGGCGCTGATCCGCGTGGTGCAGTCCATGACCCAGCTGGTGCGGCGGCCCCCCGAGGTCTTTGAGCAGGAGATCAGG CAACACTTTAGCACTGGTGGCTGGCGGCTGGTGAACCGTATCGAGTCCTGGCTGGAAACCCATGCCCTGCTGGAGAAGGCCCAGGCACTG CCCAACGGGGTGCCCAAGGCCAGCAGCTCGCCAGAGCCCCCAGCTGTAGCCGAGCTGTCAGACTCCGGCCAACAAGAACCTGAGGATGGA GGGCCAGCCCCAGGAGAGGCCTCCCAGGGCTCAGACTCAGAGGGCGGTGCCCAGGGCCTGGCCTCAGCTAGCAGGGACCACACAGACCAG ACTTCGGAGACCGCACCAGACGCATCGGTGCCACCCAGTGTGAAACCAAAGAAGCGGAGAAAGAGCTACCGGAGCTTCTTACCTGAGAAG AGTGGCTACCCTGACATCGGCTTCCCCCTCTTCCCACTTTCCAAGGGTTTCATCAAGAGCATCCGGGGTGTCCTGACGCAGTTCCGGGCT GCCCTGCTAGAGGCAGGCATGCCGGAGTGCACAGAGGACAAGTAGCTGCCAGGCACAGAGGAAAGAGCATCACCGTGGGAGAGGCCAGCC GCCGCCTGCTCACTCCCCCCCGGAATCACCCCTCTTCCCATGCCCCTCTGTCCCCACTGCAAACCCACTGCCCTCTTCTCCCCAAGGTGA GTTTGATGCTGAAGTGCAAGAAGTGTGTTGAGATGCTGCCGTTTCTATTTTGAAGCGAGCTTTCAACAGGCGGGTCCCCTGTGGCAAAGA AAATCGGAACCCTGTTGCCGATTTTCCATTTGTCACCCCAGCAGAATGTCCGGCACTTGCTCCCTTGCTGCCCCTTCTCAGGTCAGAGGC GGGTGTTCCAGGGCCTGCCGCGGGGCTCTCTGGGCCGGTTCCCTGCAGACCCGCAGGAGAGCACATGTGCCTTGCATGAAGTGTGGGTTG CGCCAACAATTCCCCTGGTCCCTTTCAACCTGTTTAGTTCAACTCAAGCCTCCCTGTGTCCCAGACCCTCCTGCTGCCACCACCACCCAG GTCCTCCCTAGTCCTCCAGCGTCAACACTATCCCTTGGGAGTTGTAGCTGCTGTCACTGACTCCCGGCTATACATGGCCTGTCGACCACG TTATAGCCCTCAGGCCTGTTGAACTTGCTCTCTAAGAGAGGTTGGGACCAGGCTAGGTTCCGGGTGACGCCCAGGAGAGGTGGTGGCCTT CACACATGCACATGGAGTTGAGGACCAGGGAGCTGCAGGGAAAGCAACAGCTATAGGTGCCTTGCTCTTCTGTCGGAGGCTGCTGGGGGC AAGAGCAGCTGCACAAGGCCAGGGCAAGTGCTAGGGCCCCTCCCCCATCACATGGTCACACTGGGACAGGCGTGCAGCTCACTGAACTCC AAGCGAGCCAGCCCTCTCTTGGACTAGAAGGCCTACTGTCAGCCCTTCGCTTACAAACTGCAGGCTCAATCCGAAGGGGACGGCCGGCGG GGGCTCTCCTAGTGCCCAGAGACAGGCCCAGAGGTTTACAAGTTTTCTAAGCTTTTGATAATGTGAAGCTCCAGGCCGAGAGGATGCTGT TGAGCACATTGCAGCTATGTAATTTTTGGTGTATGTATGTAATATTTAAGGTTGGAAAAAAAACTCAAAAGCAAAGATATTAACTCTTAT TAGAAAAAAAGACAAAAAAAAAGCCAAAGCATGATGCGTCTTGTCAGCCTTAAGTGGGCTCCACACCTGTGCTGTGCTGTGACCGCCCAG CCAGCAGAGCTGCGGGAGGATGGAGCCGGACCACACACCGTGGCATTTGGAACCGAGTCGGTATCTTGTTTGAGAAACACCCGGAGTGAC TGGTGGGGCTGTGCTTCCCAGTGCATTGTACATGTGGAGATGTGAATGCCTACTGCTTACGATATCTGTATAAAGTGCTGTGTGATTAAA CTTTTTTTTACTTGCATTTTTTTTTTTTTTTTTTTTTGTGTTGGCTCATTAGCAAGACAAGGTGACACCATTAAACCTCCCTCTGCCATT >In-frame_ENST00000300896_ENST00000319380_TCGA-C8-A273-01A_USP32_chr17_58300772_-_UBE2O_chr17_74401654_length(amino acids)=1689AA_start in transcript=195_stop in transcript=5264 MGAKESRIGFLSYEEALRRVTDVELKRLKDAFKRTCGLSYYMGQHCFIREVLGDGVPPKVAEVIYCSFGGTSKGLHFNNLIVGLVLLTRG KDEEKAKYIFSLFSSESGNYVIREEMERMLHVVDGKVPDTLRKCFSEGEKVNYEKFRNWLFLNKDAFTFSRWLLSGGVYVTLTDDSDTPT FYQTLAGVTHLEESDIIDLEKRYWLLKAQSRTGRFDLETFGPLVSPPIRPSLSEGLFNAFDENRDNHIDFKEISCGLSACCRGPLAERQK FCFKVFDVDRDGVLSRVELRDMVVALLEVWKDNRTDDIPELHMDLSDIVEGILNAHDTTKMGHLTLEDYQIWSVKNVLANEFLNLLFQVC HIVLGLRPATPEEEGQIIRGWLERESRYGLQAGHNWFIISMQWWQQWKEYVKYDANPVVIEPSSVLNGGKYSFGTAAHPMEQVEDRIGSS LSYVNTTEEKFSDNISTASEASETAGSGFLYSATPGADVCFARQHNTSDNNNQCLLGANGNILLHLNPQKPGAIDNQPLVTQEPVKLKLE DRSVVPRDVVRHMRSTDSQCGTVIDVNIDCAVKLIGTNCIIYPVNSKDLQHIWPFMYGDYIAYDCWLGKVYDLKNQIILKLSNGARCSMN TEDGAKLYDVCPHVSDSGLFFDDSYGFYPGQVLIGPAKIFSSVQWLSGVKPVLSTKSKFRVVVEEVQVVELKVTWITKSFCPGGTDSVSP PPSVITQENLGRVKRLGCFDHAQRQLGERCLYVFPAKVEPAKIAWECPEKNCAQGEGSMAKKVKRLLKKQVVRIMSCSPDTQCSRDHSME DPDKKGESKTKSEAESASPEETPDGSASPVEMQDEGAEEPHEAGEQLPPFLLKEGRDDRLHSAEQDADDEAADDTDDTSSVTSSASSTTS SQSGSGTSRKKSIPLSIKNLKRKHKRKKNKITRDFKPGDRVAVEVVTTMTSADVMWQDGSVECNIRSNDLFPVHHLDNNEFCPGDFVVDK RVQSCPDPAVYGVVQSGDHIGRTCMVKWFKLRPSGDDVELIGEEEDVSVYDIADHPDFRFRTTDIVIRIGNTEDGAPHKEDEPSVGQVAR VDVSSKVEVVWADNSKTIILPQHLYNIESEIEESDYDSVEGSTSGASSDEWEDDSDSWETDNGLVEDEHPKIEEPPIPPLEQPVAPEDKG VVISEEAATAAVQGAVAMAAPMAGLMEKAGKDGPPKSFRELKEAIKILESLKNMTVEQLLTGSPTSPTVEPEKPTREKKFLDDIKKLQEN LKKTLDNVAIVEEEKMEAVPDVERKEDKPEGQSPVKAEWPSETPVLCQQCGGKPGVTFTSAKGEVFSVLEFAPSNHSFKKIEFQPPEAKK FFSTVRKEMALLATSLPEGIMVKTFEDRMDLFSALIKGPTRTPYEDGLYLFDIQLPNIYPAVPPHFCYLSQCSGRLNPNLYDNGKVCVSL LGTWIGKGTERWTSKSSLLQVLISIQGLILVNEPYYNEAGFDSDRGLQEGYENSRCYNEMALIRVVQSMTQLVRRPPEVFEQEIRQHFST GGWRLVNRIESWLETHALLEKAQALPNGVPKASSSPEPPAVAELSDSGQQEPEDGGPAPGEASQGSDSEGGAQGLASASRDHTDQTSETA -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for USP32-UBE2O |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for USP32-UBE2O |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for USP32-UBE2O |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | USP32 | C4721610 | Carcinoma, Ovarian Epithelial | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies